Trump taking hydroxychloroquine | Assessing nonculprit lesions after STEMI | Edwards gains CE mark approval

The news came just weeks after the FDA warned against treating COVID-19 with hydroxychloroquine “outside of the hospital setting or a clinical trial” due to significant cardiovascular complications.

How should nonculprit lesions be evaluated? And when is the ideal time for complete revascularization?

The Association of Black Cardiologists (ABC) has shared resources for patients and healthcare providers focused on COVID-19’s impact on black communities and other underserved patient populations.

Edwards Lifesciences’ PASCAL transcatheter valve repair system has gained CE mark approval for treating tricuspid regurgitation (TR).

The Medical Board of California will revoke the medical license of a cardiologist accused of sexual assault.

Heart and lung surgeons are as satisfied with their jobs as ever, according to new survey results published in The Annals of Thoracic Surgery.

The Society of Cardiovascular Angiography and Interventions (SCAI) has shared a new guidance detailing the management of patients with out-of-hospital cardiac arrest (OHCA).

Omecamtiv mecarbil, a cardiac myosin activator being manufactured by Amgen and Cytokinetics to treat heart failure with reduced ejection fraction, has been granted a Fast Track designation by the FDA.

Medical imaging volume was hit hard by the COVID-19 pandemic. Fortunately, as the old adage says, this too shall pass. But when? And what should practices being doing to prepare for the return?